Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2
Related Experiment Video
Updated: May 28, 2026

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
Jing Zhang1, Shu Kan, Brian Huang
1Division of Biochemistry and Molecular Biology, Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720, USA.
Abstract:
Histone deacetylases (HDACs) are major epigenetic modulators involved in a broad spectrum of human diseases including cancers. Administration of HDAC inhibitors (HDACis) leads to growth inhibition, differentiation, and apoptosis of cancer cells. Understanding the regulatory mechanism of HDACs is imperative to harness the therapeutic potentials of HDACis. Here we show that HDACi- and DNA damage-induced apoptosis are severely compromised in mouse embryonic fibroblasts lacking a HECT domain ubiquitin ligase, Mule (Mcl-1 ubiquitin ligase E3). Mule specifically targets HDAC2 for ubiquitination and degradation. Accumulation of HDAC2 in Mule-deficient cells leads to compromised p53 acetylation as well as crippled p53 transcriptional activation, accumulation, and apoptotic response upon DNA damage and Nutlin-3 treatments. These defects in Mule-null cells can be partially reversed by HDACis and fully rescued by lowering the elevated HDAC2 in Mule-null cells to the normal levels as in wild-type cells. Taken together, our results reveal a critical regulatory mechanism of HDAC2 by Mule and suggest this pathway determines the cellular response to HDACis and DNA damage.
Insights
Mule ubiquitin ligase targets HDAC2 for degradation, impacting cancer cell apoptosis. Mule deficiency compromises responses to DNA damage and HDAC inhibitors, revealing a key regulatory pathway.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Biology
Background:
- Histone deacetylases (HDACs) are key epigenetic regulators implicated in human diseases, particularly cancers.
- HDAC inhibitors (HDACis) show therapeutic promise by inducing cancer cell apoptosis and inhibiting growth.
- Understanding HDAC regulation is crucial for optimizing HDACi-based cancer therapies.
Purpose of the Study:
- To investigate the regulatory mechanism of HDAC2.
- To elucidate the role of Mule (Mcl-1 ubiquitin ligase E3) in HDAC regulation.
- To determine the impact of Mule deficiency on cellular responses to DNA damage and HDAC inhibitors.
Main Methods:
- Utilized mouse embryonic fibroblasts deficient in Mule.
- Assessed the effects of DNA damage and Nutlin-3 treatment on Mule-null cells.
- Analyzed HDAC2 ubiquitination, degradation, p53 acetylation, and transcriptional activity.
Main Results:
- Mule deficiency led to HDAC2 accumulation due to impaired ubiquitination and degradation.
- Mule-null cells exhibited compromised p53 acetylation and activation, hindering apoptosis.
- Cellular defects in Mule-null cells were partially reversed by HDACis and fully rescued by normalizing HDAC2 levels.
Conclusions:
- Mule acts as a critical E3 ubiquitin ligase for HDAC2, targeting it for degradation.
- The Mule-HDAC2 pathway is essential for effective p53-mediated apoptosis in response to DNA damage and HDAC inhibitors.
- This pathway represents a potential therapeutic target for enhancing cancer treatment strategies.
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Anaphase Promoting Complex
Apoptosis
The Extrinsic Apoptotic Pathway
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

